Equities

Shanghai Aohua Photoelectricity Endoscope Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Shanghai Aohua Photoelectricity Endoscope Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)42.53
  • Today's Change-0.22 / -0.51%
  • Shares traded1.08m
  • 1 Year change-0.21%
  • Beta0.5391
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Aohua Photoelectricity Endoscope Co Ltd is a China-based company primarily engaged in the research and development, production, and sales of electronic endoscopic equipment and endoscopic diagnostic and surgical consumables. The Company’s endoscopic equipment includes endoscopy main units (with image processors and light sources), endoscope bodies, and peripheral endoscopic devices. The Company’s endoscopic diagnostic and surgical consumables mainly include non-vascular stents and basic consumables. The Company’s products are mainly applied in clinical departments such as gastroenterology, respiratory, otorhinolaryngology, gynecology, and emergency medicine. The Company conducts its business in the domestic and overseas markets.

  • Revenue in CNY (TTM)671.62m
  • Net income in CNY-72.38m
  • Incorporated1994
  • Employees1.22k
  • Location
    Shanghai Aohua Photoelectricity Endoscope Co LtdNo.660 Shengang Road, Songjiang DistrictSHANGHAI 201108ChinaCHN
  • Phone+86 2 154303731
  • Fax+86 2 167681020
  • Websitehttps://www.aohua.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hangzhou Ags Medtech Co Ltd668.70m272.95m4.98bn744.0018.192.00--7.443.373.378.2530.670.26733.3111.94898,793.6010.91--11.39--69.67--40.82--18.27--0.001--25.14--35.06------
Zhejiang Orient Gene Biotech Co Ltd842.11m-479.50m5.01bn2.28k--0.787--5.94-2.48-2.484.3731.550.1071.443.39369,997.60-6.6821.19-7.7726.7434.8858.52-62.4332.423.86--0.046224.780.94617.65-33.06--138.80--
Assure Tech (Hangzhou) Co Ltd462.72m120.87m5.04bn741.0041.720.9768--10.900.95110.95113.6440.620.08092.222.17624,449.302.1123.692.3028.0130.3264.6126.1147.6511.28--0.001218.787.4220.8535.8528.6963.16--
Nanjing Vishee Medical Technology Co Ltd433.83m125.95m5.42bn639.0043.033.27--12.491.321.324.5317.310.24114.0014.42678,922.307.008.397.639.2061.2471.6229.0332.766.54--0.018259.13-13.454.64-25.160.447439.73--
Hangzhou Biotest Biotech Co Ltd478.69m102.57m5.44bn603.0052.282.33--11.360.69640.69643.0615.660.19133.205.70793,854.104.0223.634.2526.2050.5756.5921.0041.4713.08--0.0000834.4226.5321.7859.0143.1244.08--
SWS Hemodialysis Care Co Ltd733.59m113.43m5.52bn1.10k48.843.13--7.530.35380.35382.295.520.35772.806.23665,688.205.235.685.836.5445.7145.7914.6116.065.25--0.001428.46-17.8031.86-63.55--24.70--
Shanghai Aohua Phtlctrcty Endscp Co Ltd671.62m-72.38m5.76bn1.22k--4.62--8.57-0.5475-0.54755.109.250.38341.022.29552,775.60-4.143.01-5.153.3461.7968.86-10.807.521.57--0.208643.3010.5420.28-63.68-16.8623.29--
Qingdao NovelBeam Technology Co Ltd571.80m174.33m5.85bn841.0033.624.44--10.231.451.454.7610.990.38170.99325.67679,901.1011.3912.7012.6114.1164.3463.1529.8433.963.4351.040.105840.95-5.9011.86-7.1113.4813.44--
Jiangsu Bioperfectus Technologies Co Ltd339.03m-25.96m5.88bn592.00--1.98--17.36-0.3096-0.30964.0435.380.09031.856.13572,683.70-0.691920.36-0.79624.5558.2262.71-7.6631.893.22--0.132928.76-13.293.9099.46---9.88--
Shenzhen Lifotronic Technology Co Ltd1.05bn251.02m5.93bn1.67k23.412.82--5.620.59070.59072.474.900.38552.515.74631,202.608.9814.0312.1017.3461.0362.4623.3027.253.00--0.140639.010.202422.125.1227.99-1.6318.64
Data as of Feb 11 2026. Currency figures normalised to Shanghai Aohua Photoelectricity Endoscope Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

40.44%Per cent of shares held by top holders
HolderShares% Held
China Universal Asset Management Co., Ltd.as of 30 Jun 202512.84m13.94%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20257.86m8.53%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 20254.14m4.50%
GF Fund Management Co., Ltd.as of 30 Jun 20252.36m2.56%
Bosera Asset Management Co., Ltd.as of 30 Jun 20252.17m2.35%
Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 20252.16m2.34%
Galaxy Asset Management Co., Ltd.as of 30 Jun 20251.66m1.81%
China Southern Asset Management Co., Ltd.as of 30 Jun 20251.42m1.54%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20251.34m1.45%
Harfor Fund Management Co., Ltd.as of 30 Jun 20251.30m1.41%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.